Search bioRxiv⌕ Search

Biology subjects

Vasireddy, V.

Publications and source records attributed to Vasireddy, V..

2 recordsLinked to original sources

Accurate de novo design of high-affinity protein binding macrocycles using deep learning

The development of macrocyclic binders to therapeutic proteins typically relies on large-scale screening methods that are resource-intensive and provide little control over binding mode. Despite considerable progress in physics-based methods for peptide design and deep-learning methods for protein design, there are currently no robust approaches for de novo design of protein-binding macrocycles. Here, we introduce RFpeptides, a denoising diffusion-based pipeline for designing macrocyclic peptide binders against protein targets of interest. We test 20 or fewer designed macrocycles against each of four diverse proteins and obtain medium to high-affinity binders against all selected targets. Designs against MCL1 and MDM2 demonstrate KD between 1-10 M, and the best anti-GABARAP macrocycle binds with a KD of 6 nM and a sub-nanomolar IC50 in vitro. For one of the targets, RbtA, we obtain a high-affinity binder with KD < 10 nM despite starting from the target sequence alone due to the lack of an experimentally determined target structure. X-ray structures determined for macrocycle-bound MCL1, GABARAP, and RbtA complexes match very closely with the computational design models, with three out of the four structures demonstrating Ca RMSD of less than 1.5 [A] to the design models. In contrast to library screening approaches for which determining binding mode can be a major bottleneck, the binding modes of RFpeptides-generated macrocycles are known by design, which should greatly facilitate downstream optimization. RFpeptides thus provides a powerful framework for rapid and custom design of macrocyclic peptides for diagnostic and therapeutic applications.

biochemistry↗

Fetal daily rhythms develop during pregnancy and entrain to the maternal circadian system

Circadian rhythms in gene expression and hormones are ubiquitous across species and differentiated cell types. This study aimed to determine when daily rhythms begin in the fetus and synchronize to the mother. We developed methods to monitor the expression of fetal PERIOD2 (PER2), a core circadian clock protein, in mice longitudinally from embryonic day (E)8.5 to E17.5 through in utero bioluminescence imaging. We found that embryonic PER2 expression increased rapidly throughout pregnancy and exhibited day-night rhythms from the start of our recordings at E8.5. The daily peak time of PER2 varied between pregnancies until it reliably peaked at night and synchronized to the mother starting around E15.5. Loss of fetal circadian rhythms associated with pregnancies that ultimately failed. Because maternal glucocorticoids have been implicated in fetal development and synchronizing circadian tissues, we tested their sufficiency to shift fetal daily rhythms in utero. Daily glucocorticoids injections over five days of late pregnancy advanced fetal PER2 rhythms in utero and blocking glucocorticoid signaling in vitro reduced PER2 synchrony between the maternal and fetal placenta by [~]40%. We conclude that fetal daily rhythms arise early in pregnancy and then synchronize with the maternal rhythm prior to birth depending, in part, on glucocorticoid signaling.

developmental biology↗